Combination of Janus Kinase Inhibitor and a Recombinant Myxoma Virus to Treat Soft Tissue Sarcomas in Dogs

Patient Disease:

Canine Soft Tissue Sarcoma

Study Name:

Combination use of a Janus Kinase Inhibitor and a Recombinant Myxoma Virus to Treat Soft Tissue Sarcomas in Dogs

Purpose of the study:

  • Evaluate the immune response to combination oclacitinib and post-operative myxoma virus injection in dogs with soft tissue sarcomas

  • Collect preliminary data to evaluate if the combination therapy might reduce tumor recurrence in dogs with soft tissue sarcomas

Primary Eligibility Criteria:

  • Biopsy-confirmed grade II or III soft tissue sarcoma that is not amenable to complete surgical resection

  • Dogs must be overall healthy with adequate blood work results

Study Protocol:

  • Pre-enrollment: Physical exam, labwork (blood tests, urinalysis), chest x-rays, and biopsy if not already performed

  • One week prior to surgery, start treatment with oclacitinib (given orally twice daily for 14 days)

  • Surgical excision of the tumor, with virus injection at the surgical site

  • Week 2: Recheck exam, labwork, and 2nd virus injection at surgery site

  • Rechecks at 4,6,8,12 weeks, and ongoing every 2 months for 12 months

Owner Responsibilities:

  • Costs of initial testing to determine eligibility (labwork, chest x-rays, and pre-treatment biopsy, as well as any other tests recommended by your pet’s oncologist)

Financial Incentives:

  • Costs related to oclacitinib therapy, myxoma virus injections, surgery (anesthesia, histopathology, hospitalization, post-operative care, wound management), clinical trial appointments, physical examinations, recommended follow-up chest x-rays, blood work, urinalysis, and immunological studies will be covered by this study.


If you have further questions about any of our clinical trials, please submit an online consulting form. Your consult will then be directed to an appropriate oncology clinician. Requests are typically returned within 5 business days.